Home › Alzheimer's Disease › Massachusetts › Brockton
Alzheimer's Disease clinical trials in Brockton, MA
4 studies for Alzheimer's Disease are looking for participants at sites in and around Brockton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
RecruitingPhase 2
- K2 Medical Research - Foxborough, Foxborough · 12 mi away
- Neurology Center of New England, Foxborough · 12 mi away
- Headlands Eastern MA LLC, Plymouth · 20 mi away
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RecruitingPhase 2
- Headlands Research-EMA, Plymouth · 20 mi away
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
RecruitingPhase 3
- Local Institution - 1663, Foxborough · 12 mi away
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RecruitingPhase 2
- K2 Medical Research, Foxborough · 12 mi away
About Alzheimer's Disease
Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills. It's the most common cause of dementia among older adults.
More about Alzheimer's Disease on MedlinePlus
Alzheimer's Disease trials in other cities
- Boston, MA26 studies
- Orlando, FL25 studies
- St. Louis, MO22 studies
- New York City, NY21 studies
- Miami, FL20 studies
- Tampa, FL17 studies
- Atlanta, GA16 studies
- The Villages, FL15 studies
- Philadelphia, PA15 studies
- Phoenix, AZ15 studies
- Indianapolis, IN14 studies
- Los Angeles, CA14 studies
Other studies in Brockton
- Breast Cancer5 studies
- Multiple Sclerosis4 studies
- Prostate Cancer4 studies
- Myasthenia Gravis3 studies
- Colon Cancer3 studies
- Non-Muscle Invasive Bladder Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.